Mattke Soeren, Seid Michael, Ma Sai
RAND Health, 1200 S Hayes St, Arlington, VA 22202, USA.
Am J Manag Care. 2007 Dec;13(12):670-6.
To assess the evidence for the effect of disease management on quality of care, disease control, and cost, with a focus on population-based programs.
Literature review.
We conducted a literature search for and a structured review of studies on population-based disease management programs, as well as for reviews and meta-analyses of disease management interventions. We identified 3 evaluations of large-scale population-based programs, as well as 10 meta-analyses and 16 systematic reviews, covering 317 unique studies.
We found consistent evidence that disease management improves processes of care and disease control but no conclusive support for its effect on health outcomes. Overall, disease management does not seem to affect utilization except for a reduction in hospitalization rates among patients with congestive heart failure and an increase in outpatient care and prescription drug use among patients with depression. When the costs of the intervention were appropriately accounted for and subtracted from any savings, there was no conclusive evidence that disease management leads to a net reduction of direct medical costs.
Although disease management seems to improve quality of care, its effect on cost is uncertain. Most of the evidence to date addresses small-scale programs targeting high-risk individuals, while only 3 studies evaluate large population-based interventions, implying that little is known about their effect. Payers and policy makers should remain skeptical about vendor claims and should demand supporting evidence based on transparent and scientifically sound methods.
评估疾病管理对医疗质量、疾病控制及成本影响的证据,重点关注基于人群的项目。
文献综述。
我们对基于人群的疾病管理项目的研究进行了文献检索和结构化综述,以及对疾病管理干预措施的综述和荟萃分析。我们确定了3项对大规模基于人群项目的评估,以及10项荟萃分析和16项系统评价,涵盖317项独特研究。
我们发现了一致的证据表明疾病管理改善了护理过程和疾病控制,但对其对健康结局的影响没有确凿支持。总体而言,疾病管理似乎不影响医疗服务利用,除了充血性心力衰竭患者住院率降低以及抑郁症患者门诊护理和处方药使用增加。当适当考虑干预成本并从任何节省中扣除时,没有确凿证据表明疾病管理会导致直接医疗成本的净降低。
尽管疾病管理似乎能改善医疗质量,但其对成本的影响尚不确定。迄今为止的大多数证据涉及针对高危个体的小规模项目,而只有3项研究评估了大规模基于人群的干预措施,这意味着对其效果知之甚少。支付方和政策制定者应继续对供应商的说法持怀疑态度,并应要求基于透明且科学合理方法的支持证据。